Fig 2 -

A) Comparison between the haplotypes of the T1DM population and those of the control population. B) Comparison of the DRB1 * 04 allelic variant of the study and control populations.</p

Flow chart of performed HLA class II typing in T1DM population.

In white the routinary steps based on “Eurospital Diabegen I and II step”; in gray the added specifc study-steps based on PCR SSP (Sequence Specific Primers) technique.</p

Autoantibodies anti-IA2, anti-IAA e anti-GAD frequencies: Age distribution.

Autoantibodies anti-IA2, anti-IAA e anti-GAD frequencies: Age distribution.</p

Comparison of haplotypes between the population with T1DM and healthy controls.

Comparison of haplotypes between the population with T1DM and healthy controls.</p

All demographic, clinical and serological details for 163 subjects affected by T1DM with HLA high-resolution.

(DOCX)</p

Comparison of the DRB1 * 04 allelic variants of the study and control populations.

The allele variants with significant p values are in bold.</p

P.I. and city of each participating ISPED centers.

<p>A. Fabrizio Barbetti (Roma), B. Corrado Mammì (Reggio Calabria), C. Maurizio Delvecchio (San Giovanni Rotondo), D₁. Nadia Tinto (Napoli), D₂. Enza Mozzillo (Napoli), E. Luigi Pianese (Ascoli Piceno), F. Sonia Toni (Firenze), G. Bruno Pasquino (Bolzano), H. Valeria Calcaterra (Pavia), I. Ivana Rabbone (Torino), J. Barbara Felappi (Brescia), K. Francesca Cardella (Palermo), L. Valentino Cherubini (Ancona), M. Franco Mammì (Locri), N. Anna Paola Frongia (Cagliari), O. Francesco Gallo (Brindisi), P. Stefano Tumini (Chieti), Q. Sonia Lucchesi (Livorno), R. Carla Maria Monciotti (Padova), S. Susanna Coccioli (Francavilla Fontana), T. Amedeo Vergerio († deceased) (Feltre), U. Stefano Zucchini (Bologna), V. Francesco Cadario (Novara), Riccardo Lera (Alessandria), X. Andrea Scaramuzza (Milano).</p

Validation of the 7-item flowchart.

<p>Phase I: The electronic records of the patients were queried (Items 1–3). Phase II, each selected patient was clinically re-evaluated (Items 4–7). IFG, impaired fasting glucose; IGT, impaired glucose tolerance. ^aFirst drop out; 18 patients were unreachable or refused to undergo clinical re-evaluation. ^bSecond drop out; 4 patients refused the genetic test.</p

Validation on the “first retrospective cohort”.

<p>(A) Percentage of MODY2 patients positive to each item of the 7-iF. (B) Percentage of MODY2 patients positive to 7, 6 or less than 6 items of the 7-iF.</p